Because our study revealed the procarcinogenic and prometastatic role of HAS2 and HA, modulation of HAS2 and HA production can be a therapeutic strategy to inhibit metastatic tumor growth in steatotic liver. Here, HAS2 is linked to metastatic neoplasm.